Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
HC Biopharma Inc.
Medical College of Wisconsin
Astellas Pharma Inc
Case Comprehensive Cancer Center
University of Miami
M.D. Anderson Cancer Center
Baptist Health South Florida
Henry Ford Health System
AstraZeneca
Enliven Therapeutics
Massachusetts General Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Centre Antoine Lacassagne
National Cancer Centre, Singapore
Washington University School of Medicine
BeiGene
Cardiff University
Cancer Trials Ireland
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
University of Oxford
Genentech, Inc.
Jazz Pharmaceuticals
Eli Lilly and Company
Processa Pharmaceuticals
University of Nebraska
Ono Pharmaceutical Co. Ltd
University of Oxford
National Cancer Institute (NCI)
Beijing Biostar Pharmaceuticals Co., Ltd.
OHSU Knight Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris
University of Nebraska
UNICANCER
Vanderbilt-Ingram Cancer Center
Sumitomo Pharma America, Inc.
Canadian Cancer Trials Group
Swiss Cancer Institute
Beijing Biostar Pharmaceuticals Co., Ltd.
Genzada Pharmaceuticals USA, Inc.
Amgen
University of Virginia
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute